scanX
Jubilant Pharmova

Jubilant Pharmova

1,127.20
-33.70
(-2.90%)
hide
Key Fundamentals
Add Ratio
Market Cap
18,490.90 Cr
EPS
52.99
PE Ratio
37.70
Dividend Yield
0.44 %
Industry
Healthcare
52 Week High
1,309.90
52 Week Low
802.00
PB Ratio
2.71
Debt to Equity
0.55
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+75.00 %
+75.00 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Jubilant Pharmova Completes USFDA Audit of Montreal Facility With 9 Observations3 days ago
Jubilant Pharmova has completed a USFDA audit of its Montreal manufacturing facility. The audit resulted in 9 observations from the regulatory authority.
neutral
Jubilant Pharmova Grants 1,506 Stock Options to Employees7 days ago
Jubilant Pharmova's Board of Directors approved the grant of 1,506 stock options/restricted stock units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. The options have an exercise price of Re. 1 each, which equals the face value per equity share. The RSUs will vest at the end of 3 years, subject to fulfillment of pre-vesting conditions. Once vested, the stock options can be exercised within a maximum period of 1 year. The vesting is subject to a minimum period of 1 year and maximum period of 5 years from the grant date as per the company's stock option plan.
neutral
Jubilant Pharmova Reports Quarterly Results and Completes API Business Transfer7 days ago
Jubilant Pharmova Limited's Board of Directors approved unaudited financial results for the quarter and half-year ended September 30, 2025. The company completed the sale and transfer of its Active Pharmaceutical Ingredients (API) business to wholly-owned subsidiary Jubilant Biosys Limited on September 1, 2025, following board approval in June and shareholder approval in July. The API business has been classified as discontinued operations in standalone results. The transaction was discharged primarily through share issuance and resulted in reversal of deferred tax liability of ₹840 million and creation of tax provision of ₹436 million. The company's continuing operations now comprise management and other support services. Consolidated results show exceptional items during the half-year including ₹217 million gain from asset sales in Maryland, USA, ₹179 million expenses from temporary suspension of Montreal facility operations, and ₹96 million amortization of debt initiation costs.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,691.40
#1 4,04,503.90
38.74
#1 54,729.00
9.71
#1 10,980
2.89
55.98
Divis Laboratories
6,656.50
1,82,735.30
71.11
9,712.00
18.67
2,191
35.10
58.39
Cipla
1,505.70
1,21,284.30
22.36
28,409.50
7.12
5,291
3.71
40.84
Torrent Pharmaceuticals
3,580.00
1,21,163.50
60.51
11,539.40
6.99
1,911
30.46
50.54
Dr Reddys Laboratories
1,205.40
1,00,587.70
#1 17.53
33,741.20
16.73
5,725
-0.38
37.06
Mankind Pharma
2,261.80
95,310.10
52.66
12,744.20
#1 20.90
2,007
-21.05
25.15
Zydus Life Science
944.10
94,998.60
18.88
23,511.00
18.55
4,615
34.60
33.87
Lupin
1,971.80
89,318.30
20.71
22,909.50
13.74
3,306
#1 72.75
53.33
Alkem Laboratories
5,668.50
67,476.50
29.08
13,458.30
3.70
2,216
21.39
63.91
Aurobindo Pharma
1,123.80
66,246.20
19.24
32,345.60
9.43
3,484
3.81
53.78
Growth Rate
Revenue Growth
7.67 %
Net Income Growth
1,050.34 %
Cash Flow Change
10.38 %
ROE
900.75 %
ROCE
151.75 %
EBITDA Margin (Avg.)
17.88 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
1,928
1,891
1,968
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
1,587
1,611
1,631
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
341
280
337
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
17 %
14 %
17 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
95
98
105
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
53
49
50
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
206
154
190
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
55
52
70
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
151
103
120
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37
9.71
6.49
7.59
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
3,577
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
Investments
0
85
103
124
115
69
241
239
256
42
44
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
3,907
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
2,165
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
4,353
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
6,239
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
Share Capital
16
16
16
16
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
132
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
513
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
1,072
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433
-1,453
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
47.68 %
47.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
17.22 %
17.40 %
16.57 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
7.05 %
9.53 %
10.52 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
17.75 %
17.97 %
18.02 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
7.31 %
7.42 %
7.22 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673
93,336

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 5
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.44

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
 01 Feb 2021 886.60 886.60
06 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 05 Aug 2021 843.05 657.45
12 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
 11 Aug 2022 397.10 353.35
10 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
 10 Aug 2023 362.90 404.75
02 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 02 Aug 2024 703.90 866.20
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 849.00 920.60
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Oct 2024 1,228.25 1,108.05
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 937.70 954.95
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 16 May 2025 896.35 905.60
25 Jul 2025 DIVIDEND Dividend
₹ 5.00 /share
 25 Jul 2025 905.60 1,175.00
29 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Jul 2025 1,210.30 1,174.20
29 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Aug 2025 1,119.10 1,039.30
31 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Oct 2025 1,097.50 1,118.40

Announcements

USFDA Communication Montreal Canada3 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Approval For Grant Of Stock Options/Rsus7 days ago
Un-Audited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30 20257 days ago
Board Meeting Outcome for Meeting Held On October 31 20257 days ago
Letter To Shareholders Whose KYC Is Not UpdatedOct 27, 2025
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025Oct 14, 2025
Press Release Pertaining To The Launch Of New High-Speed Isolator Based Line At Its Spokane Manufacturing Facility In The US By Jubilant Hollisterstier LLC USA A Wholly-Owned Subsidiary Of The CompanyOct 10, 2025
Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign"Oct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 01, 2025
Allotment Of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) By Jubilant Biosys Limited A Wholly Owned Subsidiary CompanyOct 01, 2025
Closure of Trading WindowSep 30, 2025
Closure of Trading WindowSep 30, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 23, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On September 23 2025Sep 23, 2025
Disclosure Under Regulation 30 - Jubilant Pharmova Announces Completion Of Pharmacovigilance Inspection By The USFDA With No ObservationsSep 20, 2025
Reminder Email Sent To Shareholders Intimating About The 100 Days CampaignSep 12, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Orders Passed By The Additional Commissioner Central Tax (Appeals) MysuruSep 02, 2025
Disclosure Under Regulation 30 - Completion Of Sale And Transfer Of API BusinessSep 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 01, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorSep 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Intimation Regarding A Letter Dispatched To The Shareholders For Annual Report Of The Company For FY 2024-25Aug 05, 2025
Reg. 34 (1) Annual Report.Aug 05, 2025
Notice Of 47Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2024-25Aug 05, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 05, 2025
E-Mail Communication To Shareholders Intimating About Deduction Of Tax At Source (TDS) On Final Dividend For FY 2024-25Aug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Completion Of Pre-Approval Inspection (PAI) By USFDA Of Solid Dosage Manufacturing Facility At Roorkee IndiaAug 02, 2025
Submission Of Communication Sent To Shareholders Relating To Notice Of Transfer Of Equity Shares / Dividend To Investor Education And Protection Fund AuthorityAug 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 29, 2025
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Jul 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2025
Grant Of Stock OptionsJul 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 29, 2025
Unaudited Results For The Quarter Ended June 30 2025Jul 29, 2025
Board Meeting Outcome for Approval Of Unaudited Financial ResultsJul 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 24, 2025
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025Jul 23, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Kotak Multicap Fund Direct - Growth
0.00%
-1842613
-0.98%
-0.96%
Bandhan Small Cap Fund Direct-Growth
0.00%
-1697961
-1.16%
-1.08%
Bandhan Focused Fund Direct-Growth
0.00%
-754950
-4.13%
-3.19%
Kotak Special Opportunities Fund Direct-Growth
0.00%
-650000
-3.75%
-3.53%
Kotak Contra Fund Direct-Growth
0.00%
-578400
-1.32%
-1.32%
HDFC Manufacturing Fund Direct - Growth
0.00%
-500000
-0.47%
-0.44%
Kotak MNC Fund Direct-Growth
0.00%
-362006
-1.79%
-1.70%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-317568
-1.81%
-1.70%
Kotak Consumption Fund Direct - Growth
0.00%
-281413
-1.94%
-1.93%
Bandhan Innovation Fund Direct-Growth
0.00%
-252341
-1.52%
-1.37%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-244236
-0.54%
-0.52%
Kotak Healthcare Fund Direct - Growth
0.00%
-140000
-3.26%
-3.07%
Aditya Birla Sun Life Bal Bhavishya Yojna Direct-Growth
0.00%
-105213
-1.00%
-0.83%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-103804
-0.44%
-0.41%
Bandhan Business Cycle Fund Direct-Growth
0.00%
-103786
-0.70%
-0.67%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.00%
-94886
-1.23%
-1.15%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-60752
-0.44%
-0.41%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
-34986
-1.17%
-1.08%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-22230
-0.44%
-0.41%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
-21907
-0.44%
-0.41%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.00%
-8161
-0.20%
-0.18%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-7298
-0.44%
-0.41%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-5185
-0.44%
-0.41%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-4705
-0.43%
-0.41%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.00%
-4382
-0.11%
-0.10%

Technical Indicators

RSI(14)
Neutral
51.66
ATR(14)
Volatile
39.51
STOCH(9,6)
Neutral
61.46
STOCH RSI(14)
Neutral
66.95
MACD(12,26)
Bullish
3.56
ADX(14)
Weak Trend
19.14
UO(9)
Bearish
52.30
ROC(12)
Uptrend And Accelerating
2.82
WillR(14)
Neutral
-47.96
Bearish
2
Neutral
5
Bullish
2

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Website
https://www.jubl.com
Chairperson NameShyam S Bhartia
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104